Bowles Erin J Aiello, Walker Rod L, Anderson Melissa L, Dublin Sascha, Crane Paul K, Larson Eric B
Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, United States of America.
Department of Epidemiology, University of Washington, Seattle, Washington, United States of America.
PLoS One. 2017 Jun 20;12(6):e0179857. doi: 10.1371/journal.pone.0179857. eCollection 2017.
We evaluated dementia and Alzheimer's disease (AD) risks after a cancer diagnosis in a population-based prospective cohort, the Adult Changes in Thought (ACT) study.
We followed community-dwelling people aged ≥65 years without dementia at study entry for incident dementia and AD from 1994-2015. We linked study data with cancer registry data and categorized cancer diagnoses as prevalent (diagnosed before ACT study enrollment) or incident (diagnosed during follow-up). We used Cox regression to estimate cause-specific hazard ratios (HRs) with 95% confidence intervals (CIs) for dementia or AD risk comparing people with a cancer diagnosis to people without cancer. We conducted sensitivity analyses restricted to people surviving beyond age 80, and stratified by cancer stage, type, and whether the cancer was smoking-related.
Among 4,357 people, 756 (17.4%) had prevalent cancer; 583 (13.4%) developed incident cancer, 1,091 (25.0%) developed dementia, and 877 (20.1%) developed AD over a median 6.4 years (34,482 total person-years) of follow-up. Among complete cases (no missing covariates) with at least one follow-up assessment, adjusted HRs for dementia following prevalent and incident cancer diagnoses were 0.92 (95%CI: 0.76, 1.11) and 0.87 (95%CI: 0.64, 1.04), compared to no cancer history. HRs for AD were 0.95 (95%CI: 0.77, 1.17) for prevalent cancer and 0.73 (95%CI: 0.55, 0.96) for incident cancer. In sensitivity analyses, prevalent late-stage cancers were associated with reduced risks of dementia (HR = 0.51, 95%CI: 0.30, 0.89) and AD (HR = 0.50, 95%CI: 0.27, 0.94). When limited to people who survived beyond age 80, incident cancers were still associated with reduced AD risk (HR = 0.69, 95%CI: 0.51, 0.92).
Our results do not support an inverse association between prevalent cancer diagnoses, which were primarily early-stage, less aggressive cancers, and risk of dementia or AD. A reduced risk of AD following an incident cancer diagnosis is biologically plausible but may reflect selective mortality.
在一项基于人群的前瞻性队列研究——成人思维变化(ACT)研究中,我们评估了癌症诊断后的痴呆症和阿尔茨海默病(AD)风险。
我们对1994年至2015年期间年龄≥65岁、入组时无痴呆症的社区居住人群进行随访,观察其新发痴呆症和AD情况。我们将研究数据与癌症登记数据相链接,并将癌症诊断分为既往存在(ACT研究入组前诊断)或新发(随访期间诊断)。我们使用Cox回归来估计特定病因的风险比(HRs)及95%置信区间(CIs),以比较有癌症诊断者与无癌症者患痴呆症或AD的风险。我们进行了敏感性分析,仅限于80岁以上存活者,并按癌症分期、类型以及癌症是否与吸烟相关进行分层。
在4357人中,756人(17.4%)有既往癌症;583人(13.4%)患新发癌症,1091人(25.0%)患痴呆症,877人(20.1%)患AD,中位随访时间为6.4年(总计34482人年)。在至少有一次随访评估的完整病例(无协变量缺失)中,与无癌症病史者相比,既往癌症诊断和新发癌症诊断后痴呆症的校正HR分别为0.92(95%CI:0.76,1.11)和0.87(95%CI:0.64,1.04)。既往癌症诊断和新发癌症诊断后AD的HR分别为0.95(95%CI:0.77,1.17)和0.73(95%CI:0.55,0.96)。在敏感性分析中,既往晚期癌症与痴呆症风险降低相关(HR = 0.51,95%CI:0.30,0.89)以及与AD风险降低相关(HR = 0.50,95%CI:0.27,0.94)。当仅限于80岁以上存活者时,新发癌症仍与AD风险降低相关(HR = 0.69,95%CI:0.51,0.92)。
我们的结果不支持主要为早期、侵袭性较小癌症的既往癌症诊断与痴呆症或AD风险之间存在负相关。新发癌症诊断后AD风险降低在生物学上是合理的,但可能反映了选择性死亡。